Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $21.00

Plus Therapeutics (NASDAQ:PSTV) had its target price lifted by equities researchers at Ascendiant Capital Markets from $20.50 to $21.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research firms have also commented on PSTV. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of Plus Therapeutics in a research note on Thursday, September 25th. HC Wainwright decreased their target price on Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Saturday, September 27th. Maxim Group lowered their price objective on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, August 18th. Finally, Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Plus Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.00.

Plus Therapeutics Price Performance

PSTV opened at $0.73 on Monday. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. The firm has a market capitalization of $72.58 million, a PE ratio of -0.33 and a beta of 0.81. The company’s 50-day moving average is $0.54 and its 200 day moving average is $0.55.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.08. The company had revenue of $1.39 million during the quarter, compared to analysts’ expectations of $1.08 million. As a group, analysts expect that Plus Therapeutics will post -2.3 EPS for the current year.

Insider Transactions at Plus Therapeutics

In other Plus Therapeutics news, Director Robert P. Lenk purchased 110,000 shares of Plus Therapeutics stock in a transaction on Friday, August 22nd. The shares were acquired at an average cost of $0.49 per share, for a total transaction of $53,900.00. Following the completion of the transaction, the director directly owned 139,327 shares of the company’s stock, valued at approximately $68,270.23. The trade was a 375.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Jane Street Group LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned about 0.19% of Plus Therapeutics as of its most recent SEC filing. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.